Piccart M J, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J-A, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W
EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium.
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8. doi: 10.1111/j.1525-1438.2003.13357.x.
Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.
美国妇科肿瘤学组和一个欧洲-加拿大联合研究小组进行的两项独立且连续的随机临床试验表明，对于晚期上皮性卵巢癌女性患者，作为一线化疗方案，顺铂-紫杉醇方案在临床缓解率、无进展生存期和总生存期方面优于顺铂-环磷酰胺方案。这些研究结果在中位随访约3年时发表，现已有6.5年随访的更新结果：在每种情况下，紫杉醇组的生存绝对获益为11%；这一优势在统计学和临床上均具有显著性，支持紫杉醇在晚期卵巢癌一线化疗中的作用。
